Drugs / GVV858
last change Dec 2025 re-read 2 minutes ago

GVV858

Developed for
castration-resistant prostate carcinoma · hormone receptor-positive breast cancer
Investigated by
Novartis Pharmaceuticals

Trials 1 · a red edge is where a trial was stopped

202620272028202920302031
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07288359 Dec 2025 → May 2031 expected castration-resistant prostate carcinoma, hormone receptor-positive breast cancer Novartis Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GVV858 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07288359